Marco Maruzzo, Head of the Oncology 3 Unit and Medical Oncology Consultant specializing in genitourinary (GU) cancer at Veneto Institute of Oncology IOV – IRCCS, shared on LinkedIn:
“The perioperative treatment landscape of bladder cancer is rapidly evolving with the introduction of ICI/ADC-based strategies. However, direct randomized comparisons among contemporary regimens are lacking. Along with Brigida Anna Maiorano we have tried to to compare the efficacy of perioperative systemic treatment strategies for MIBC with a network meta-analysis of RCTs.”
Title: Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials
Authors: Brigida Anna Maiorano, Matteo Maruzzo, A. Ślusarczyk, Juan D. Subiela, Francesco Soria, Stefano Albisinni, Alessandro Mari, Francesco Claps, Raffaele Contieri, Andrea Gallioli, Javier Caño-Velasco, Daniele D’Andrea, Ekaterina Laukhtina, Guillaume Marcq, Wojciech Krajewski, Etienne Grobet-Jeandin, Luca Afferi, Francesco Del Giudice, Alessio Rizzo, Matteo Moschini, Lodewijk S. Mertens, Alessandro Cigliola, Chiara Mercinelli, Marco Piacentini & Matteo Santoni, Bertrand Pradère, Andrea Necchi
Read also “European Commission Approved Pembrolizumab Plus Enfortumab Vedotin for Cisplatin-Ineligible Resectable MIBC” on OncoDaily.
